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Endometrial cancer: a frequent
orphan disease
Endometrial cancer is the most frequent invasive cancer of the
female genital tract, with an estimated annual incidence of
almost 38 000 in the ‘old’ European Union (before 1 May
2004) and a similar figure in the United States. It is substan-
tially more frequent than ovarian cancer, but can be cured
more often by surgery and radiation therapy; this results in
about 9000 deaths per year in the EU and 7000 in the United
States [1,2]. Epidemiological risk factors for endometrial can-
cer are well known [3], but the optimal therapy of endometrial
cancer has been poorly investigated. While there exists a cer-
tain consensus for surgical therapy in so far as a total abdomi-
nal hysterectomy and bilateral salpingo-oophorectomy should
be performed, the value of pelvic and paraaortic lympha-
denectomy remains unproven. Indeed, the frequently cited
rationale for retroperitoneal lymphadenectomy, namely the
avoidance of adjuvant radiation therapy for node-negative dis-
ease, may be wrong in the light of a recently published trial,
GOG-99 [4].
The role of adjuvant radiation therapy has been defined
much more clearly in recent years, at least for patients with
stage I and very early stage II disease. Pelvic radiation therapy
dramatically reduced the risk of locoregional recurrence in
three randomised controlled trials [4–6], regardless of whether
or not retroperitoneal lymphadenectomy was part of the stan-
dard surgical procedure. None of these trials revealed a signifi-
cant beneficial effect of radiotherapy on survival.
The adjuvant medical therapy of endometrial cancer
remains poorly investigated. A systematic review and meta-
analysis of the Cochrane Collaboration revealed that the adju-
vant use of progestational agents may indeed be dangerous.
They do not significantly reduce the risk of recurrence and
endometrial cancer-related death, but significantly increase the
risk of non-cancer-related death [7]. Numerous small trials
have investigated the efficacy of adjuvant chemotherapy in
endometrial cancer, but were not adequately powered to detect
a difference in survival (reviewed in [8]). Adjuvant chemo-
therapy with doxorubicin and cisplatin has been compared
with whole abdominal radiation therapy in stage III and IV
disease, and chemotherapy turned out to be superior to radio-
therapy with regards to progression-free (hazard ratio 0.81)
and overall survival (hazard ratio 0.71; P < 0.05) [9].
Similarly, the knowledge base for the therapy of recurrent
and metastatic endometrial cancer is small at present. High
doses of oral medroxyprogesterone acetate were not found to
be more active than lower doses [10]. For cytotoxic chemother-
apy, phase I and II trials are abundant, but while they are useful
to estimate the efficacy of drugs, they do not contribute to
defining the best choice of therapy. A few major randomised
controlled trials are nevertheless available (Table 1) in addition
to numerous small trials (reviewed in [8]). The combination of
doxorubicin and cisplatin is considered standard therapy based
upon two trials [11,12] that revealed a very moderate advan-
tage of the combination over single drug doxorubicin, despite
the greater toxicity experienced with the combination.
An important trial reported in this issue of Annals of Onco-
logy builds upon this foundation and on the promising activity
of paclitaxel in phase II trials. The randomised comparison of
the standard three-weekly doxorubicin (60 mg/m2) plus cispla-
tin (50 mg/m2) with doxorubicin (50 mg/m2) plus paclitaxel
(150 mg/m2 as a 24-h infusion) plus filgrastim was performed
in an exemplary manner, based upon sound principles of clini-
cal trial design. The randomisation yielded comparable groups
of patients, and the selection of patients represented the popu-
lation of endometrial cancer patients. Despite promising
results from preliminary trials and the activity of paclitaxel in
a phase III trial [13], the chemotherapy regimens did not differ
significantly in terms of activity and toxicity. While this may
seem disappointing, at least two points are illustrated:
(i) promising observations in phase II trials may be due to
patient selection bias and need not be confirmed in random-
ised trials; and (ii) cisplatin or carboplatin may be essential in
the therapy of endometrial cancer. The latter hypothesis is
supported by two very recent trials [13,14].
A more general issue, however, also deserves a mention:
certain neoplasias that are much rarer than endometrial cancer
have been far better investigated. For instance, only 8000
cases of Hodgkin’s disease are diagnosed annually in the
United States, and a similar number is expected for the Euro-
pean Union; a substantial majority of these patients can be
cured by chemotherapy and/or radiotherapy, such that  1300
patients a year die from Hodgkin’s disease in the United
States [2]. A long series of trials organised by many collabora-
tive groups in different countries have optimised chemother-
apy and radiotherapy to the current state of the art, which
allows the majority of patients, even with advanced stage
Hodgkin’s disease, to be cured. By comparison, endometrial
cancer appears to be a poorly investigated orphan disease
indeed, despite its frequent occurrence. A substantial decrease
in the incidence of endometrial cancer is unlikely in the next
few years, and early detection methods have not been proven
to have a major impact on mortality [15]. Thus, our efforts
should be focused on improving all treatment modalities for
endometrial cancer. Such progress will have to begin in the
minds of those who care for patients with endometrial cancer.
This tumour is neither rarer nor less interesting than other
neoplasias that have been studied successfully. In addition to
elucidating the molecular events that lead to and characterise
endometrial cancer, the oncology community is obliged to set
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up and complete clinical trials of endometrial cancer surgery,
radiation therapy and medical therapy. At present, the North
American Gynecologic Oncology Group is leading the way,
but despite regulatory agencies increasingly threatening clinical
research, similar contributions will have to be made in Europe.
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Table 1. Major randomised controlled trials of chemotherapy for advanced endometrial cancer
Trial No. of
patients
Randomised chemotherapy regimens Median progression-
free survival
Median survival Comment
Thigpen et al.,
1993 [11]
223 Doxorubicin versus doxorubicin + cisplatin 3.9 versus 6.2 months
van Wijk et al.,
2003 [12]
177 Doxorubicin versus doxorubicin + cisplatin 7 versus 8 months 7 versus 9 months Significant survival benefit
for patients with good
performance status
Thigpen et al.,
1994 [16]
356 Doxorubicin versus doxorubicin +
cyclophosphamide
3.2 versus 3.9 months 6.7 versus 7.3 months
Fleming et al.,
2004 [13]
266 Doxorubicin + cisplatin versus doxorubicin +
cisplatin + paclitaxel + G-CSF
At 5 months, 50%
versus 67%
At 12 months, 50%
versus 58%
Gallion et al.,
2003 [17]
342 Standard timed doxorubicin + cisplatin versus
circadian timed doxorubicin + cisplatin
6.5 versus 5.9 months 11.2 versus 13.2 months
Weber et al.,
2003 [14]
63 Doxorubicin + cisplatin versus carboplatin +
paclitaxel
At 15 months, 24%
versus 35%
At 15 months, 27%
versus 41%
Randomised phase II trial
Fleming et al.,
2004 [18]
317 Doxorubicin + cisplatin versus doxorubicin +
paclitaxel + G-CSF
7.2 versus 6.0 months 12.6 versus 13.6 months
G-CSF, granulocyte colony-stimulating factor.
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